1. የሳንባ ካንሰር ምርመራ እና የመጀመሪያ ህክምና
ታካሚ ሉ በነሀሴ 26, 2005 በሳንባ አዶኖካርሲኖማ እና ሊምፍ ኖድ ሜታስታሲስ ታውቋል. የግራ የታችኛው ሎቤክቶሚ በሴፕቴምበር 22 ቀን 2005 ተካሂዷል. እ.ኤ.አ. ነሐሴ 4 ቀን 3 በፕሌይራል ፍንዳታ ምክንያት የምርመራው ውጤት በተደጋጋሚ መገኘቱ የተረጋገጠ ሲሆን በታርሴቫ ታክማለች (የዑደቶቹ ብዛት አይታወቅም)። በጃንዋሪ 2007, 8 የካንሰር እድገት በድጋሚ ምርመራ ላይ ተገኝቷል, ከዚያም የታርሴቫ ህክምና ቆመ እና የሊቢታ ህክምና ለ 2008 ዑደቶች ተጀመረ. በዚሁ ጊዜ የአከርካሪ አጥንት ሂፕ ሜታስታሲስ ተገኝቷል እና 16 የዜታይ ዑደቶች ተካሂደዋል.
2. ለመጀመሪያ ጊዜ በክሊኒካዊ ሙከራዎች ውስጥ ለመሳተፍ, ሁኔታው በቁጥጥር ስር ነው.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the እብጠት was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. በሁለተኛው ክሊኒካዊ ሙከራ ውስጥ ዕጢው በግልጽ ጠፋ.
On August 6, 2012, Mr. Lu participated in the AP26113 drug ክሊኒካዊ ሙከራ at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the በአንጎል ውስጥ ዕጢ decreased and became large.
4. ብርቅዬ የጂን ሚውቴሽን ያግኙ እና በአዲስ ክሊኒካዊ ሙከራዎች ውስጥ ለመሳተፍ በጉጉት ይጠብቁ
በጁላይ 2014 ድጋሚ ምርመራ የሙሉ ሰውነት PET አሳይቷል፡ የአንጎል ቁስሎች በመሠረቱ የተረጋጋ እና ደረቱ ግልጽ የሆነ እድገት ነበረው። በሜይ 12፣ 2014፣ ተጠርጣሪው ፀረ-AP26113 ሊምፍ (3 ሴሎች፣ ትልቁ 1.1 ሴ.ሜ) የሰለጠኑ የሕዋስ መስመሮች በማሳቹሴትስ አጠቃላይ ሆስፒታል ተካሂደው AP26113 መውሰድ ቀጠሉ።
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s ኒውሮብላስትማ and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunotherapy phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
